Emerald Advisers LLC Acquires New Position in Hims & Hers Health, Inc. $HIMS

Emerald Advisers LLC acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 305,921 shares of the company’s stock, valued at approximately $17,352,000. Emerald Advisers LLC owned about 0.14% of Hims & Hers Health at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of HIMS. Quent Capital LLC acquired a new stake in shares of Hims & Hers Health during the 3rd quarter worth approximately $28,000. Virtus Advisers LLC purchased a new position in Hims & Hers Health in the second quarter worth approximately $26,000. Quaker Wealth Management LLC acquired a new stake in Hims & Hers Health during the second quarter worth $29,000. Bessemer Group Inc. raised its position in Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after purchasing an additional 312 shares during the period. Finally, Hilltop National Bank acquired a new position in shares of Hims & Hers Health in the 3rd quarter valued at $35,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

HIMS has been the subject of a number of recent analyst reports. Barclays started coverage on Hims & Hers Health in a research report on Monday, December 8th. They set an “overweight” rating and a $48.00 price objective for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, December 29th. Citigroup restated a “sell” rating on shares of Hims & Hers Health in a report on Monday, January 5th. Bank of America increased their price objective on shares of Hims & Hers Health from $28.00 to $32.00 and gave the stock an “underperform” rating in a research report on Tuesday, November 4th. Finally, KeyCorp assumed coverage on Hims & Hers Health in a research report on Tuesday, October 21st. They issued a “sector weight” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $44.54.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $28.83 on Thursday. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. Hims & Hers Health, Inc. has a 52-week low of $23.97 and a 52-week high of $72.98. The firm has a market cap of $6.56 billion, a PE ratio of 53.39, a price-to-earnings-growth ratio of 5.16 and a beta of 2.37. The company’s 50 day moving average is $35.20 and its two-hundred day moving average is $45.31.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The company had revenue of $598.98 million for the quarter, compared to analysts’ expectations of $578.99 million. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The firm’s revenue was up 49.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.32 EPS. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health announced that its board has authorized a share buyback plan on Monday, November 17th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the company to purchase up to 3% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board of directors believes its shares are undervalued.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Deborah M. Autor sold 7,054 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $258,952.34. Following the completion of the transaction, the insider owned 6,175 shares in the company, valued at $226,684.25. The trade was a 53.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Irene Becklund sold 8,411 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $308,767.81. Following the completion of the sale, the insider owned 2,126 shares in the company, valued at $78,045.46. The trade was a 79.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 134,611 shares of company stock worth $4,895,914. Corporate insiders own 13.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.